Log in to save to my catalogue

Antiviral and immunomodulatory interferon-beta in high-risk COVID-19 patients: a structured summary...

Antiviral and immunomodulatory interferon-beta in high-risk COVID-19 patients: a structured summary...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_2aa163bf6ba144c59bd6baf7f80b7679

Antiviral and immunomodulatory interferon-beta in high-risk COVID-19 patients: a structured summary of a study protocol for a randomised controlled trial

About this item

Full title

Antiviral and immunomodulatory interferon-beta in high-risk COVID-19 patients: a structured summary of a study protocol for a randomised controlled trial

Publisher

England: BioMed Central Ltd

Journal title

Current controlled trials in cardiovascular medicine, 2021-09, Vol.22 (1), p.584-584, Article 584

Language

English

Formats

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

The primary objective of the study is to demonstrate the efficacy of low-dose IFN-β in reducing the risk of SARS-CoV-2 recently infected elderly patients to progress towards severe COVID-19 versus control group within 28 days. Secondary objectives are: 1) To assess the reduction in Intensive Care Unit (ICU) admission in patients treated with IFN-β...

Alternative Titles

Full title

Antiviral and immunomodulatory interferon-beta in high-risk COVID-19 patients: a structured summary of a study protocol for a randomised controlled trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_2aa163bf6ba144c59bd6baf7f80b7679

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_2aa163bf6ba144c59bd6baf7f80b7679

Other Identifiers

ISSN

1745-6215

E-ISSN

1745-6215

DOI

10.1186/s13063-021-05367-6

How to access this item